RESUMEN
This paper aims to explore the main points of diagnosis, treatment and misdiagnosis of conversion disorder characterized by paroxysmal abdominal pain. The general hospitals had a high misdiagnose rate and no effective symptomatic treatment for conversion disorder patients with physical discomfort as main symptoms, which leading to heavy physical and mental burden of patients and waste of medical resources, so this paper retrospectively analyzed the etiology, diagnostic process, treatment and therapeutic effect of a case of conversion disorder with paroxysmal abdominal pain as the main symptom. Case analysis showed that the physical discomfort as chief complain of conversion disorder patients affected the rate of early correct diagnosis and treatment, so clinicians' ability of diagnosis and differential diagnosis of conversion disorder needs to be strengthened. At the same time, cognitive behavioral therapy (CBT) is effective in the clinical treatment and recurrence prevention of conversion disorder.
RESUMEN
Objective:To analyze and summarize the drug registration clinical trial for rheumatic diseases in China from January 2013 to November 2019.Methods:The website of CDE was searched to obtain the data and statistical analysis was conducted.Results:①The number of drug clinical trials for rheumatic diseases in China increased year by year and the total was 525. The registered indications mainly included diffuse connective tissue disease, spondylo arthritis, metabolic diseases and degenerative diseases, including rheumatoid arthritis (RA) (189), gout (122), osteoarthritis (OA) (89), ankylosing spondylitis (AS) (60) and systemic lupus erythematosus (SLE) (39). ② The phaseⅡ-Ⅲ clinical trials were mainly for biological disease-modifying antirheumatic drugs (bDMARDs). Most of the bioequivalence test (BE) were chemical drugs.③ The domestically developed chemicals and biological included BLyS/APRIL, CD22, JAK1, S1P1 and BTK. ④ Adalimumab and tocilizumab accounted for the largest proportion of biosimilar drugs. The indications were mainly RA. ⑤ The number of international multi-center clinical trials increased year by year, with the indications mainly for RA and SLE.Conclusion:① The overall number of drugs trials for rheumatic diseases in China has been increasing rapidly in recent years. ② The research and development of chemicals and biologics is the trend. ③ Significant achievements have been made in the research and development of biosimilars in China and it is expected to benefit more patients by broaden the indications.
RESUMEN
Objective To observe the clinical characteristics of ankylosing spondylitis (AS) patients with hyperuricemia (HUA), and to understand the correlation between AS and HUA, so as to improve the understanding of AS patients with HUA. Methods A retrospective analysis was carried out in patients with the diagnosis with AS from November 2012 to August 2016. Patients were divided into two groups based on complicated with and without HUA. The clinical manifestations, inflammatory indicators, imaging manifest-ations, treatment and outcomes of the two groups were statistically analyzed, and the follow-up results of some patients with HUA were analyzed. The chi-square test was used for the counting data. The measurement data in line with the normal distribution were tested by t test, and the measurement data in non-normal distribution were tested by Mann-Whitney U test. Results Three hundred and sixty-two patients with AS were collected, consisting of 288 males (79.6%) and 74 females (20.4%), aged from 14 to 72 years, a course of disease was 3 months to 40 years. There were 87 cases (24.0%) with hyperuricemia, 77 cases were male (88.5%, 21.3%of all AS patients), and 10 were female (11.5%, 2.8% of all AS patients). Shorter morning stiffness time [(13 ±31) min and (22 ±48) min, Z=-2.231, P=0.026], lower IgM level [(1.4 ±1.3) g/L and (3.0 ±4.3) g/L, Z=-2.040, P=0.041], and lower erythrocyte sedimentation rate [(25±17) mm/1 h and (33±22) mm/1 h, t=-2.617, P=0.007] in the HUA group when compared with patients without HUA. The difference between the two groups was statistically significant. Four cases (4.6%) had gout arthritis in the group with HUA, all were male, blood uric acid level all>420 μmol/L. There were 7 cases (8.0%) of urolithiasis in the group with HUA, and 24 cases (8.7%) of urolithiasis in the group without HUA, but there was no statistically significant difference in the incidence of urolithiasis between the two groups. None developed hypertensive disease, heart disease, nephropathy, or diabetis. Conclusion The incidence of hyperuricemia is high in AS, and with lower disease activity, and fewer complications.
RESUMEN
Various studies have shown that the high expression of matrix metalloproteinase-3 (MMP-3) is involved and play an important role in the degradation of the extracellular matrix of synovium, cartilage and subchondral bone of rheumatoid arthritis(RA). Tissue inhibitor of metalloproteinase 1 (TIMP-1) binds specifically to MMP-3 and inhibits the activity of MMP-3. The balance of MMP-3 / TIMP-1 plays an important role in the clinical outcome of RA. New research found that inhibiting Th17 cell differentiation, maintaining Treg (regulatory T cell) activity and regulating Th17/ Treg balance may provide novel targets for the treatment of RA. Further study found that the expression of MMP-3 and Interleukin 17(IL-17) in the peripheral blood of RA patients was significantly increased, the two were positively correlated, and the decrease of Treg could affect the balance of MMP-3/TIMP-1. This article will review the mechanism of MMP-3/TIMP-1 and Th17 /Treg in RA and its clinical significance.
RESUMEN
Diabetes mellitus combined with depression, which is complicated and difficult to control, is closely relatedwith each other both physically and mentally. According to"variable-stable and sequential eight methods", created byProfessor Fan Guanjie, we treat diabetes mellitus combined with depression by persevering the whole perpetual motionand syndrome differentiation, integrating psychological adjustment and lifestyle interventions into prevention andtreatment of disease, which embodies the clinical advantages of multiple approaches, targets, and effects of TCM, therebyadjusting both the body and spirit, and the two diseases.
RESUMEN
Objective To explore the composition principles of prescriptions for simple obesity based on the analysis of medical literature issued in recently 30 years about Chinese medicine for simple obesity. Methods We collected literature of Chinese medicine in treating simple obesity from VIP, CNKI, Wanfang, CBM and CMCC/CMCI databases, and screened out the formulas for simple obesity to establish a formula database. And then the medication rules were figured out with the Traditional Chinese medicine Inheritance Support System version 2.5 (TCMISS 2.5) software. Results A total of 57 formulas were screened out. And the top 10 herbs with highest occurrence frequency in the prescriptions were Poria, Rhizoma Atractylodis Macrocephalae, Rhizoma Alismatis, Radix et Rhizoma Rhei, Fructus Crataegi, Radix Astragali, Radix Glycyrrhizae, Folium Nelumbinis, Pericarpium Citri Reticulatae and Semen Cassiae. After data mining, we got 13 high-frequency herb-pair combinations and 31 core combinations, and 8 new prescriptions were extracted. Conclusion The research has achieved the quantitative description of the relationship between the Chinese medicines, the extraction of the core combinations and the discovery of new Chinese medicine prescriptions for simple obesity. The results will provide references for the development of new Chinese medicines for the treatment of simple obesity .